
The Joint Clinical Assessment has changed what a European launch dossier has to prove. What it has not changed is when that proof has to[…]

The scientific argument about biosimilar switching was settled some years ago. In a joint statement issued in September 2022, EMA and the Heads of Medicines[…]

For as long as EU medicines have been regulated, the summary of product characteristics and package leaflet have been Word documents that become PDFs that[…]

The EU Health Technology Assessment Regulation stopped being theoretical in 2026. The Member State Coordination Group on HTA endorsed the first Joint Clinical Assessment report[…]

Very few marketing authorisation holders run every part of their pharmacovigilance system in-house. Case processing, literature screening, local safety contacts and database hosting are routinely[…]

After more than two years of negotiation, the EU’s pharmaceutical legislation reform has a settled text. The Council and the European Parliament reached political agreement[…]

A post-authorisation safety study is one of the few pharmacovigilance activities where a regulator reviews your methodology before you are allowed to begin. Get the[…]

The environment has become a regulatory obligation for pharmaceutical companies on two fronts at once. On one side sits the marketing authorisation dossier, where the[…]

Antimicrobial resistance is one of the most serious long-term threats to European health systems, yet the pipeline of new antibiotics has thinned to a trickle.[…]

Prefilled syringes, pens, autoinjectors and inhalers are medicines to their manufacturers and patients — but the device that delivers the dose has its own regulatory[…]